Parkinson Disease Signs | Resting Tremor | Rigidity | Bradykinesia | Postural reflex impairment
Item
idiopathic parkinson's disease as indicated by the presence of at least two of the following signs: resting tremor, rigidity, bradykinesia, or postural reflex impairment
boolean
C0030567 (UMLS CUI [1,1])
C0311392 (UMLS CUI [1,2])
C0234379 (UMLS CUI [2])
C0026837 (UMLS CUI [3])
C0233565 (UMLS CUI [4])
C1868839 (UMLS CUI [5])
Antiparkinson Agents Stable | Pharmaceutical Preparations unchanged
Item
stable anti-parkinson medication regimen, with no change in medications in the 4 weeks prior to study entry
boolean
C0003405 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0442739 (UMLS CUI [2,2])
Antidepressive Agents | Antipsychotic Agents
Item
no antidepressant or antipsychotic medications within 30 days prior to study entry
boolean
C0003289 (UMLS CUI [1])
C0040615 (UMLS CUI [2])
Pharmacotherapy | Psychotherapy | Behavior Therapy | Study Subject Participation Status
Item
agree not to start other pharmacotherapy, psychotherapy, or behavior therapy while participating in the trial
boolean
C0013216 (UMLS CUI [1])
C0033968 (UMLS CUI [2])
C0004933 (UMLS CUI [3])
C2348568 (UMLS CUI [4])
Contraceptive methods Acceptable
Item
acceptable methods of contraception
boolean
C0700589 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
Able to read Instructions written English Language | Instructions Oral English Language Compliance Ability
Item
ability to read and/or follow written and oral instructions presented in english
boolean
C0586740 (UMLS CUI [1,1])
C1442085 (UMLS CUI [1,2])
C1576874 (UMLS CUI [1,3])
C0376245 (UMLS CUI [1,4])
C1442085 (UMLS CUI [2,1])
C0442027 (UMLS CUI [2,2])
C0376245 (UMLS CUI [2,3])
C3714738 (UMLS CUI [2,4])
C0085732 (UMLS CUI [2,5])
Cognitive status Sufficient Informed Consent Related | Mini-mental state examination
Item
sufficient cognitive ability (baseline mini-mental status > 24) to provide informed consent
boolean
C0945985 (UMLS CUI [1,1])
C0205410 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0439849 (UMLS CUI [1,4])
C0451306 (UMLS CUI [2])
Heart Diseases | Liver diseases | Kidney Diseases | Hematological Disease | Respiration Disorders | Endocrine System Diseases | Vascular Diseases | Metabolic Diseases | System Abnormality Relevant Clinical
Item
history of cardiac, hepatic, renal, hematologic, respiratory, endocrine, vascular, metabolic, or other systems abnormalities that are clinically relevant in the opinion of study officials
boolean
C0018799 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0018939 (UMLS CUI [4])
C0035204 (UMLS CUI [5])
C0014130 (UMLS CUI [6])
C0042373 (UMLS CUI [7])
C0025517 (UMLS CUI [8])
C0449913 (UMLS CUI [9,1])
C1704258 (UMLS CUI [9,2])
C2347946 (UMLS CUI [9,3])
C0205210 (UMLS CUI [9,4])
Laboratory test result abnormal
Item
certain abnormal laboratory values
boolean
C0438215 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Investigational New Drugs
Item
use of an investigational drug within 3 months of study entry
boolean
C0013230 (UMLS CUI [1])
ST. JOHN'S WORT EXTRACT | Natural Products Mood Enhancement
Item
use of st. john's wort or any other "natural" product known to have mood enhancing properties in the 30 days prior to study entry
boolean
C0813171 (UMLS CUI [1])
C1566558 (UMLS CUI [2,1])
C0026516 (UMLS CUI [2,2])
C2349975 (UMLS CUI [2,3])
Selegiline | Monoamine Oxidase Inhibitors
Item
selegiline or other monoamine oxidase inhibitor within the 6 weeks prior to study entry
boolean
C0036579 (UMLS CUI [1])
C0026457 (UMLS CUI [2])
Anti-Anxiety Agents Use Regular | taking medication to help sleep Habitual | Narcotics Use Infrequent | Temazepam | Melatonin | zolpidem
Item
regular usage of anti-anxiety medications or habitual use of sleep medications, although occasional use of certain hypnotics (temazepam, melatonin, or zolpidem) is allowed
boolean
C0040616 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,3])
C2054158 (UMLS CUI [2,1])
C0205353 (UMLS CUI [2,2])
C0027415 (UMLS CUI [3,1])
C1524063 (UMLS CUI [3,2])
C0521114 (UMLS CUI [3,3])
C0039468 (UMLS CUI [4])
C0025219 (UMLS CUI [5])
C0078839 (UMLS CUI [6])
Psychotherapy Initiation
Item
psychotherapy initiated in the 6 months prior to study entry
boolean
C0033968 (UMLS CUI [1,1])
C1704686 (UMLS CUI [1,2])
Bipolar Disorder | Hypomania | Mania | Schizophrenia | Psychotic Disorders
Item
history of bipolar disorder, hypomania, mania, schizophrenia, or other psychotic disorder
boolean
C0005586 (UMLS CUI [1])
C0241934 (UMLS CUI [2])
C0338831 (UMLS CUI [3])
C0036341 (UMLS CUI [4])
C0033975 (UMLS CUI [5])
Suicide attempt Serious | Suicidal tendency Serious | Potential Suicidal Serious
Item
serious suicidal attempt in the 12 months prior to study entry or serious suicidal tendencies/potential
boolean
C0038663 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0235196 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C3245505 (UMLS CUI [3,1])
C0438696 (UMLS CUI [3,2])
C0205404 (UMLS CUI [3,3])
Dopamine Antagonists | Metoclopramide | Haloperidol
Item
use of dopamine receptor antagonist (metoclopramide, haloperidol)
boolean
C0242702 (UMLS CUI [1])
C0025853 (UMLS CUI [2])
C0018546 (UMLS CUI [3])
Parkinsonian Disorders Secondary Due to Pharmaceutical Preparations | Dopamine Antagonists | Metabolic Diseases | Cerebrovascular Disorders | Encephalitis | Degenerative disorder
Item
secondary parkinsonian symptoms due to drugs (including dopamine receptor antagonists), metabolic disorders, cerebrovascular disease, encephalitis, or other degenerative diseases
boolean
C0242422 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,4])
C0242702 (UMLS CUI [2])
C0025517 (UMLS CUI [3])
C0007820 (UMLS CUI [4])
C0014038 (UMLS CUI [5])
C1285162 (UMLS CUI [6])